Global Information
회사소개 | 문의

아시네토박터 감염증 : 파이프라인 리뷰

Acinetobacter Infections - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 255983
페이지 정보 영문 169 Pages
가격
US $ 2,000 ₩ 2,278,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,557,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,836,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


아시네토박터 감염증 : 파이프라인 리뷰 Acinetobacter Infections - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 169 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

아시네토박터는 그람음성간균입니다. 아시네토박터 감염증은 흔히 볼 수 없는 감염증이나, 발병하면 일반적으로 액체 내용물(기도 및 뇌척수액, 복수, 요로 등)이 많은 장기계에 영향을 미칩니다. 증상은 열(고체온), 붉은 부종, 열 또는 통증을 동반하는 피부, 창상 등입니다. 소인으로 약한 면역계, 열악한 위생 상태, 최신 수술 및 시술을 받지 못하는 것 등을 들 수 있습니다.

세계의 아시네토박터 감염증(Acinetobacter Infections) 치료제 개발 동향에 대해 조사했으며, 파이프라인 제품의 각 개발 단계 비교 분석, 약제 표적, 작용기서, 투여 경로, 분자 종류별 치료제 평가, 이 부문의 최신 동향, 주요 기업 리뷰 등의 정보를 전해드립니다.

서론

  • 조사 범위

아시네토박터 감염증 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

아시네토박터 감염증 : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

아시네토박터 감염증 치료제 개발에 참여하고 있는 기업

  • Achaogen Inc
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • Atterx Biotherapeutics Inc
  • AvidBiotics Corp
  • Emergent BioSolutions Inc
  • Entasis Therapeutics Inc
  • Evaxion Biotech ApS
  • F. Hoffmann-La Roche Ltd
  • FOB Synthesis Inc
  • Hsiri Therapeutics LLC
  • LegoChem Biosciences Inc
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Novabiotics Ltd
  • Omnia Molecular Ltd
  • Peptilogics Inc
  • Pfizer Inc
  • Redx Pharma Plc
  • Sarepta Therapeutics Inc
  • Sealife PHARMA GMBH
  • Shionogi & Co., Ltd.
  • Techulon Inc
  • Tetraphase Pharmaceuticals Inc
  • Vaxdyn SL
  • Xellia Pharmaceuticals ApS

약제 개요

휴지중인 프로젝트

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 17.06.20

List of Tables

  • Number of Products under Development for Acinetobacter Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Acinetobacter Infections - Pipeline by ABAC Therapeutics SA, H2 2018
  • Acinetobacter Infections - Pipeline by Achaogen Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Acies Bio doo, H2 2018
  • Acinetobacter Infections - Pipeline by AiCuris GmbH & Co KG, H2 2018
  • Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corp, H2 2018
  • Acinetobacter Infections - Pipeline by Appili Therapeutics Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals Inc, H2 2018
  • Acinetobacter Infections - Pipeline by AstraZeneca Plc, H2 2018
  • Acinetobacter Infections - Pipeline by Atterx Biotherapeutics Inc, H2 2018
  • Acinetobacter Infections - Pipeline by C3J Therapeutics Inc, H2 2018
  • Acinetobacter Infections - Pipeline by ContraFect Corp, H2 2018
  • Acinetobacter Infections - Pipeline by Destiny Pharma Plc, H2 2018
  • Acinetobacter Infections - Pipeline by Entasis Therapeutics Inc, H2 2018
  • Acinetobacter Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Acinetobacter Infections - Pipeline by Hsiri Therapeutics LLC, H2 2018
  • Acinetobacter Infections - Pipeline by KBP BioSciences Co Ltd, H2 2018
  • Acinetobacter Infections - Pipeline by LegoChem Biosciences Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Meiji Seika Pharma Co Ltd, H2 2018
  • Acinetobacter Infections - Pipeline by Melinta Therapeutics Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Novabiotics Ltd, H2 2018
  • Acinetobacter Infections - Pipeline by Octagon Therapeutics Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Oxford Drug Design Ltd, H2 2018
  • Acinetobacter Infections - Pipeline by Peptilogics Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Pfizer Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Redx Pharma Plc, H2 2018
  • Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H2 2018
  • Acinetobacter Infections - Pipeline by Shionogi & Co Ltd, H2 2018
  • Acinetobacter Infections - Pipeline by Spero Therapeutics Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Summit Therapeutics Plc, H2 2018
  • Acinetobacter Infections - Pipeline by Techulon Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018
  • Acinetobacter Infections - Pipeline by Vaxdyn SL, H2 2018
  • Acinetobacter Infections - Pipeline by Venus Medicine Research Center, H2 2018
  • Acinetobacter Infections - Pipeline by Xellia Pharmaceuticals ApS, H2 2018
  • Acinetobacter Infections - Dormant Projects, H2 2018

List of Figures

  • Number of Products under Development for Acinetobacter Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H2 2018, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.

Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene and recent surgery or procedure.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acinetobacter Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Acinetobacter Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acinetobacter Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 37 and 21 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 7 molecules, respectively.

Acinetobacter Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acinetobacter Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Acinetobacter Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acinetobacter Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acinetobacter Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acinetobacter Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acinetobacter Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acinetobacter Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Acinetobacter Infections - Overview
  • Acinetobacter Infections - Therapeutics Development
  • Acinetobacter Infections - Therapeutics Assessment
  • Acinetobacter Infections - Companies Involved in Therapeutics Development
  • Acinetobacter Infections - Drug Profiles
  • Acinetobacter Infections - Dormant Projects
  • Acinetobacter Infections - Discontinued Products
  • Acinetobacter Infections - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research